Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Billionaire investor Ray Dalio says dollar bulls should worry about crypto.

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...